Genmab (Denmark)

Recent papers from Genmab (Denmark)

1. Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trialThe Lancet Haematology · 2026
2. Exposure–Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular LymphomaClinical Pharmacokinetics · 2026
3. First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphomaHemaSphere · 2026
4. MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FLBlood Advances · 2026
5. Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability TradeoffsMolecular Cancer Therapeutics · 2026
6. A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumorsInternational Journal of Clinical Oncology · 2026
7. Mechanisms reducing parasympathetic activity in chronic hypoxiaThe Journal of Physiology · 2026
8. Epcoritamab (epcor) + chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) eligible for autologous stem cell transplant (ASCT): Pooled results from arms 4 and 10 of EPCORE NHL-2.Journal of Clinical Oncology · 2026
9. Safety and Efficacy of HexaBody ‐ DR5 / DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed HepatotoxicityClinical and Translational Science · 2026
10. Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 studyGynecologic Oncology · 2026
11. Brain glucose extraction is not fixed and may compensate for changes in cerebral blood flow—Commentary article on “Brain glucose extraction is fixed at 10% despite twofold variability in resting cerebral blood flow in healthy humans”Journal of Cerebral Blood Flow & Metabolism · 2026
12. Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trialHaematologica · 2026
13. Epcoritamab monotherapy as outpatient treatment for patients with relapsed/refractory diffuse large B-cell lymphoma: Interim results from EPCORE NHL-6Clinical Lymphoma Myeloma & Leukemia · 2026
14. Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trialAnnals of Hematology · 2026
15. Brain aerobic glycolysis is stable during adulthood: Direct evidence from cross-brain blood sampling in 239 healthy adultsJournal of Cerebral Blood Flow & Metabolism · 2026
16. Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphomaBlood · 2025
17. Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete responseBlood · 2025
18. Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trialBlood · 2025
19. Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safetyBlood · 2025
20. Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient populationBlood · 2025